[go: up one dir, main page]

NO20074710L - 1H-Imidazole derivatives as cannabinoid CB2 receptor modulators - Google Patents

1H-Imidazole derivatives as cannabinoid CB2 receptor modulators

Info

Publication number
NO20074710L
NO20074710L NO20074710A NO20074710A NO20074710L NO 20074710 L NO20074710 L NO 20074710L NO 20074710 A NO20074710 A NO 20074710A NO 20074710 A NO20074710 A NO 20074710A NO 20074710 L NO20074710 L NO 20074710L
Authority
NO
Norway
Prior art keywords
imidazole derivatives
cannabinoid
receptor modulators
receptors
compounds
Prior art date
Application number
NO20074710A
Other languages
Norwegian (no)
Inventor
Herman H Van Stuivenberg
Josephus H M Lange
Bernard J Van Vliet
Original Assignee
Solvay Pharm Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Bv filed Critical Solvay Pharm Bv
Publication of NO20074710L publication Critical patent/NO20074710L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Foreliggende oppfinnelse angår en gruppe 1H-imidazolderivater som er modulatorer av cannabinoid-CB2-reseptorer, fremgangsmåter for fremstilling av disse forbindelsene, nye intermediater anvendelige ved syntese av nevnte imidazolderivater, fremgangsmåter for fremstilling av disse intermediatene, farmasøytiske sammensetninger som inneholder et eller flere av disse 1H-imidazolderivatene som aktiv ingredies, så vel som anvendelse av disse farmasøytiske sammensetningene for behandling av forstyrrelser hvori cannabinoid-CB2-reseptorer er involvert. Forbindelsene har den generelle formelen (I) hvori R1-R4 har betydningene gitt i foreliggende beskrivelse.The present invention relates to a group of 1H-imidazole derivatives which are modulators of cannabinoid CB2 receptors, processes for the preparation of these compounds, novel intermediates useful in the synthesis of said imidazole derivatives, processes for preparing these intermediates, pharmaceutical compositions containing one or more of them. The 1H-imidazole derivatives as active ingredient, as well as the use of these pharmaceutical compositions for the treatment of disorders involving cannabinoid CB2 receptors. The compounds have the general formula (I) wherein R1-R4 has the meanings given in the present description.

NO20074710A 2005-02-16 2007-09-14 1H-Imidazole derivatives as cannabinoid CB2 receptor modulators NO20074710L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65309105P 2005-02-16 2005-02-16
EP05101171 2005-02-16
PCT/EP2006/060009 WO2006087355A1 (en) 2005-02-16 2006-02-16 1h-imidiazole derivatives as cannabinoid cb2 receptor modulators

Publications (1)

Publication Number Publication Date
NO20074710L true NO20074710L (en) 2007-09-14

Family

ID=36216936

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074710A NO20074710L (en) 2005-02-16 2007-09-14 1H-Imidazole derivatives as cannabinoid CB2 receptor modulators

Country Status (9)

Country Link
EP (1) EP1874734A1 (en)
JP (1) JP2008530179A (en)
AU (1) AU2006215567B2 (en)
BR (1) BRPI0607439A2 (en)
CA (1) CA2597896A1 (en)
IL (1) IL184006A0 (en)
NO (1) NO20074710L (en)
RU (1) RU2410377C2 (en)
WO (1) WO2006087355A1 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007292155B2 (en) * 2006-09-05 2012-11-01 Kyowa Kirin Co., Ltd. Imidazole derivative
FR2908766B1 (en) * 2006-11-20 2009-01-09 Sanofi Aventis Sa PYRROLE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THERAPEUTICS.
WO2009026407A1 (en) * 2007-08-22 2009-02-26 Allergan, Inc. Pyrrole compounds having sphingosine-1-phosphate receptor agonist or antagonist biological activity
WO2009131957A2 (en) 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising oxadiazole derivatives
US20110237528A1 (en) * 2008-09-19 2011-09-29 Institute For Oneworld Health Compositions and methods comprising imidazole and triazole derivatives
AU2011210765A1 (en) 2010-01-28 2012-09-13 President And Fellows Of Harvard College Compositions and methods for enhancing proteasome activity
US9556166B2 (en) 2011-05-12 2017-01-31 Proteostasis Therapeutics, Inc. Proteostasis regulators
SG11201400974VA (en) * 2011-09-28 2014-09-26 Fujifilm Corp Crystal of 5-hydroxy-1h-imidazole-4-carboxamideˑ3/4 hydrate, method for producing the same and crystal of 5-hydroxy-1h-imidazole-4-carboxamide hydrate
WO2013147160A1 (en) * 2012-03-29 2013-10-03 東レ株式会社 Cyclic amine derivative and use thereof for medical purposes
US9849135B2 (en) 2013-01-25 2017-12-26 President And Fellows Of Harvard College USP14 inhibitors for treating or preventing viral infections
ES2669977T3 (en) * 2013-06-12 2018-05-29 Kaken Pharmaceutical Co., Ltd. 4-Alkynylimidazole derivative and medicine that comprises it as an active ingredient
WO2015073528A1 (en) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
HK1248226A1 (en) * 2015-06-22 2018-10-12 Sumitomo Dainippon Pharma Co., Ltd. 1,4-di-substituted imidazole derivative
CN107922348A (en) * 2015-06-22 2018-04-17 大日本住友制药株式会社 Bicyclic Heterocyclic Amide Derivatives
WO2017146128A1 (en) 2016-02-26 2017-08-31 大日本住友製薬株式会社 Imidazolylamide derivative
TW201803869A (en) 2016-04-27 2018-02-01 健生藥品公司 6-aminopyridin-3-yl thiazoles as modulators of ROR[gamma]t
US11034658B2 (en) 2018-06-18 2021-06-15 Janssen Pharmaceutica Nv Pyridinyl pyrazoles as modulators of RORγT
CA3103770A1 (en) * 2018-06-18 2019-12-26 Janssen Pharmaceutica Nv Phenyl and pyridinyl substituted imidazoles as modulators of roryt
JP2021528405A (en) 2018-06-18 2021-10-21 ヤンセン ファーマシューティカ エヌ．ベー． Amide-substituted thiazole as a modulator of RORγt
US10975057B2 (en) 2018-06-18 2021-04-13 Janssen Pharmaceutica Nv 6-aminopyridin-3-yl pyrazoles as modulators of RORgT
RU2725878C1 (en) * 2019-12-30 2020-07-07 Федеральное государственное бюджетное учреждение науки Федеральный исследовательский центр "КОМИ научный центр Уральского отделения Российской академии наук" Chiral myrtanyl sulphonamides

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2032671C1 (en) * 1990-06-29 1995-04-10 Сумитомо Кемикал Компани Лимитед Derivatives of 1-phenylimidazole showing insecticide properties and insecticide composition
PT1098885E (en) * 1998-07-23 2005-01-31 Fujisawa Pharmaceutical Co IMIDAZOLE COMPOUNDS AND ITS USE AS ADENOSIN DISEASE DEHYMENASE INHIBITORS
JP2004502642A (en) * 2000-02-11 2004-01-29 ブリストル−マイヤーズ　スクイブ　カンパニー Cannabinoid receptor modulators, methods for their production, and use of cannabinoid receptor modulators for the treatment of respiratory and non-respiratory diseases
EP1844020B1 (en) * 2005-01-10 2017-09-06 Exelixis, Inc. Heterocyclic carboxamide compounds as steroid nuclear receptor ligands

Also Published As

Publication number Publication date
BRPI0607439A2 (en) 2010-04-06
IL184006A0 (en) 2007-10-31
WO2006087355A1 (en) 2006-08-24
RU2410377C2 (en) 2011-01-27
AU2006215567A1 (en) 2006-08-24
AU2006215567B2 (en) 2011-05-12
JP2008530179A (en) 2008-08-07
CA2597896A1 (en) 2006-08-24
RU2007134428A (en) 2009-03-27
EP1874734A1 (en) 2008-01-09

Similar Documents

Publication Publication Date Title
NO20074710L (en) 1H-Imidazole derivatives as cannabinoid CB2 receptor modulators
NO20041171L (en) 1H-imidazole derivatives with CB1 agonistic, CB1 delagonistic or CB1 antagonistic activity
WO2009010871A3 (en) Pyrazole derivatives as antagonists of adenosine a3 receptor
UY31796A (en) CONDENSED CYCLOPENTANOCARBOXYL ACID DERIVATIVES SUBSTITUTED WITH ACILAMINE AND ITS USE AS PHARMACEUTICAL PRODUCTS.
NO20051870L (en) 1H-1,2,4-triazole-3-carboxamide derivatives as cannabinoid CB1 receptor ligands
NO20083500L (en) 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive-allosteric modulators of mGluR2 receptors
NO20064456L (en) Thiadiazolidinones as GSK-3 inhibitors
UA103198C2 (en) Squaramide derivatives as cxcr2 antagonists
MX2010007587A (en) Compounds comprising a cyclobutoxy group.
EA201190004A1 (en) CONDENSED IMIDAZOLE CARBOXAMIDE AS TRPV3 MODULATORS
NO20082285L (en) 3-Aminocyclopentanecarboxamides as modulators of chemokine receptors
NO20070487L (en) 3-aminocyclopentanecarboxamides as modulators of chemokine receptors.
BRPI0607309A2 (en) processes for the preparation of substituted phenylpyrazole urea
NO20065678L (en) 3- (4-heteroarylcyclohexylamino) cyclopentanecarboxamides as modulators of chemokine receptors.
NO20083193L (en) 4,5-Dihydro- (1H) -pyrazole derivatives as cannabinoid CB1 receptor modulators
NO20091766L (en) Spiro-piperidine
EA200870606A1 (en) SERO-CONTAINING DERIVATIVES OF PYRAZOL AS AN ELECTORAL ANTAGONISTS OF CANA CANNABINOID RECEPTOR
WO2010073128A3 (en) Fused imidazole derivatives as trpv3 antagonist
MA32479B1 (en) Compounds new active as muscarinic receptor antagonists
TW200714587A (en) Biphenyl compounds useful as muscarinic receptor antagonists
UA100862C2 (en) Hexatomic aromatic compounds, preparation and use thereof
EA201170721A1 (en) 3-AMINOCYCLOPENTANCARBOXAMIDES AS A CHEMOCIN RECEPTOR MODULATORS
WO2008109027A3 (en) Tri-aryl/heteroaroaromatic cannabinoids and use thereof
NO20062249L (en) 1H-imidazole derivatives as cannabionide receptor modulators
WO2009034432A8 (en) Novel compounds active as muscarinic receptor antagonists

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application